Chaoju Eye Care Holdings Ltd. (HK:2219)
:2219
Want to see HK:2219 full AI Analyst Report?
Top Page
Chaoju Eye Care Holdings Ltd.
(2219)
Select Model
Select Model
Rating:75Outperform
Price Target:
HK$3.00
▲(10.70% Upside)
Action:UpgradedDate:04/25/26
The score is driven primarily by stable financial health (strong margins and a conservative balance sheet) tempered by weaker recent growth and a sharp drop in free cash flow. Technicals are supportive with an uptrend across key moving averages, while valuation stands out as a major positive due to the low P/E and high dividend yield.
Positive Factors
Sustained Profitability
High, multi-level margins imply the core ophthalmic services and product mix generate durable operating economics. Sustained gross and EBIT margins provide capacity to absorb cost pressures, fund medical staff and facility upkeep, and support reinvestment into higher-margin surgical services over several quarters.
Negative Factors
Top-line Weakness
A decline in revenue signals softening demand or competitive pressure that can erode scale economics. Persistent top-line weakness limits operating leverage, makes margin recovery harder, and raises risk that investment in facilities or recruiting ophthalmologists will deliver lower incremental returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Profitability
High, multi-level margins imply the core ophthalmic services and product mix generate durable operating economics. Sustained gross and EBIT margins provide capacity to absorb cost pressures, fund medical staff and facility upkeep, and support reinvestment into higher-margin surgical services over several quarters.
Read all positive factors
Chaoju Eye Care Holdings Ltd. (2219) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.02B
Dividend Yield9.29%
Average Volume (3M)722.53K
Price to Earnings (P/E)9.6
Beta (1Y)0.76
Revenue Growth-3.21%
EPS Growth-7.36%
CountryHK
Employees2,608
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.11
Shares Outstanding705,180,500
10 Day Avg. Volume521,468
30 Day Avg. Volume722,533
Financial Highlights & Ratios
PEG Ratio-1.34
Price to Book (P/B)0.71
Price to Sales (P/S)1.29
P/FCF Ratio15.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.25
Revenue Forecast (FY)HK$1.47B
Chaoju Eye Care Holdings Ltd. Business Overview & Revenue Model
Company Description
Chaoju Eye Care Holdings Limited owns and operates a network of ophthalmic hospitals and optical centers in China. Its consumer ophthalmic services include treatments and prevention for various ophthalmic disorders, such as refractive and presbyop...
How the Company Makes Money
Chaoju Eye Care makes money primarily by charging patients for ophthalmic medical services delivered through its eye hospitals and clinics, and by selling vision-care products through its optical centers. Key revenue streams typically include: (1)...
Chaoju Eye Care Holdings Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
84
Very Positive
Cash Flow
56
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.33B | 1.41B | 1.37B | 990.04M | 997.79M |
| Gross Profit | 559.05M | 611.30M | 621.13M | 434.70M | 448.67M |
| EBITDA | 378.62M | 335.37M | 434.82M | 267.87M | 304.65M |
| Net Income | 178.70M | 195.08M | 228.91M | 187.75M | 161.75M |
Balance Sheet | |||||
| Total Assets | 3.02B | 2.88B | 2.92B | 2.72B | 2.51B |
| Cash, Cash Equivalents and Short-Term Investments | 1.49B | 1.54B | 1.55B | 1.68B | 1.78B |
| Total Debt | 237.74M | 218.01M | 200.80M | 196.16M | 178.65M |
| Total Liabilities | 612.92M | 554.76M | 544.38M | 424.68M | 378.11M |
| Stockholders Equity | 2.40B | 2.32B | 2.36B | 2.27B | 2.11B |
Cash Flow | |||||
| Free Cash Flow | 112.58M | 354.36M | 286.02M | 148.29M | 189.18M |
| Operating Cash Flow | 339.41M | 354.36M | 372.57M | 273.41M | 249.39M |
| Investing Cash Flow | -460.60M | 245.36M | -654.10M | -464.77M | -578.51M |
| Financing Cash Flow | -132.87M | -292.30M | -204.01M | -165.43M | 1.19B |
Chaoju Eye Care Holdings Ltd. Technical Analysis
Positive
2.71
Price Trends
2.68
Positive
2.67
Positive
2.73
Positive
Market Momentum
0.06
Negative
64.54
Neutral
69.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2219, the sentiment is Positive. The current price of 2.71 is above the 20-day moving average (MA) of 2.68, above the 50-day MA of 2.68, and below the 200-day MA of 2.73, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 64.54 is Neutral, neither overbought nor oversold. The STOCH value of 69.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2219.
Chaoju Eye Care Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$2.02B | 9.59 | 7.66% | 9.29% | -3.21% | -7.36% | |
71 Outperform | HK$682.16M | 2.28 | 5.29% | 9.14% | -1.48% | 549.60% | |
69 Neutral | HK$853.79M | 5.69 | 6.49% | 1.99% | -1.61% | -27.39% | |
67 Neutral | HK$1.40B | 5.35 | 18.05% | 4.37% | -4.23% | 3.95% | |
64 Neutral | HK$1.55B | 20.66 | 5.64% | 1.20% | 1.75% | ― | |
52 Neutral | HK$1.65B | 117.78 | 0.48% | 0.49% | -2.63% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:2219
Chaoju Eye Care Holdings Ltd.
2.87
0.28
10.81%
HK:1526
Rici Healthcare Holdings Ltd.
0.88
-0.11
-11.11%
HK:1846
EuroEyes International Eye Clinic Limited
2.70
-0.06
-2.17%
HK:3309
C-MER Eye Care Holdings Limited
1.24
-0.42
-25.30%
HK:3689
Guangdong Kanghua Healthcare Co., Ltd. Class H
2.02
0.23
12.85%
HK:3886
Town Health International Medical Group Ltd.
0.24
>-0.01
-2.46%
Chaoju Eye Care Holdings Ltd. Corporate Events
Chaoju Eye Care Sets 2026 AGM to Approve Dividend, Board Mandates and Share Issue Authority
Apr 21, 2026
Chaoju Eye Care Holdings Limited has called its annual general meeting for May 12, 2026 in Beijing, where shareholders will review the audited financial statements for the year ended December 31, 2025 and vote on a proposed final dividend of HK$0....
Chaoju Eye Care Places RMB340 Million in BOC Wealth Management and Structured Deposits
Apr 1, 2026
Chaoju Eye Care Holdings’ subsidiary Chaoju Medical Technology has subscribed to a Bank of China institutional wealth management product with a principal amount of RMB260 million, funded by the group’s surplus cash rather than proceeds...
Chaoju Eye Care Declares Final 2025 Dividend of HK$0.2423 per Share
Mar 31, 2026
Chaoju Eye Care Holdings has proposed a final ordinary cash dividend of HK$0.2423 per share for the financial year ended 31 December 2025, underscoring management’s confidence in the group’s performance and cash generation. Subject to ...
Chaoju Eye Care Profit Slips in 2025 as Revenue Declines but Network Expands
Mar 31, 2026
Chaoju Eye Care reported a 3.2% decline in 2025 revenue to RMB1.36 billion and a 4.7% drop in net profit to RMB177.4 million, with net margin edging down to 13.0% despite a slightly higher pre-tax margin. Non-IFRS adjusted net profit also weakened...
Chaoju Eye Care Sets March 31 Board Meeting to Approve 2025 Results and Consider Final Dividend
Mar 9, 2026
Chaoju Eye Care Holdings Limited has scheduled a board meeting for 31 March 2026 to review and approve the group’s annual results for the year ended 31 December 2025 and to authorize their publication. The board will also deliberate on wheth...
Chaoju Eye Care to Relocate Hong Kong Principal Office to IFC in 2026
Feb 27, 2026
Chaoju Eye Care Holdings Limited has announced that it will relocate its principal place of business in Hong Kong to Level 9, One International Finance Centre, 1 Harbour View Street, Central, Hong Kong, effective 1 March 2026. The move to a prime ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.